When my vet (lameness go-to guy in these parts) suggested Cosequin ASU for one of my beasties I asked him about that study and another I found (see below) - specifically about the numbers. The amounts of ASU they recommended were significantly lower than what’s in the Cosequin ASU. He was confident that the stuff worked and said “Some initial thoughts when I read this article previously was that the model used is not a degenerate joint disease model but an inflammation model…” He spoke to Nutramax and got back to me with an answer that satisfied me, though I can’t remember all the particulars. I do remember that they said the ASU product they have can be used to up the amount of ASU in the Cosequin or on its own.
[I]Recent studies have shown that Avocado-Soybean unsaponifiables may be of use as a chondroprotective; however, there is a glaring disparity in the milligram levels proven effective clinically, and the milligrams recommended for use in commercial products. The most recent study conducted at Colorado State University, on experimentally induced equine osteoarthritis, established the recognized benchmark for oral ASU, by producing a noticeable change in the disease progression using 6 grams of ASU daily. While this dose (6g) meets the criteria of the authors as a DMOAD, commercially available products fall well short of clinical parameters. Currently products available to consumers such as Cosequin ASU (1 gram ASU) and Platinum Performance CJ (2 grams ASU) provide a mere 1/6 and 1/3 of the proven relevant dosing respectively. As a clinician or a consumer one should be well- informed about the facts prior to recommending or purchasing products that may not provide an efficacious level of the desired compounds. Full and timely disclosure of available data may help clear up this confusion in the future.
Colorado State Equine Osteoarthritis Model: as published in VLS round table discussion supplement to Compendium Equine vol. 3, no. 2 (A-March, 2008)
http://www.vlsstore.com/media/publicationsarticle/nutramax_rt_v3no2a_0308.pdf
This study was a blinded, experimentally controlled, randomized
block design that used 16 horses in an established model
of OA. On20day 0 of the study, arthroscopic surgery was performed
and OA was induced in the midcarpal joint of all horses.
Also on day 0, horses were divided into two groups: placebo
and ASU-treatment. The placebo group (n = 8) received molasses
orally one time daily, whereas the ASU-treated group (n = 8)
received 6 g (6,000mg) of ASU and a similar volume of molasses
orally; both treatments were continued throughout the study
0D
period. On day 14, horses began treadmill exercise, which
continued for the remaining 8 weeks of the study. All horses
completed the study, and no adverse events were recorded.
At the termination of the study, horses treated with ASU were
observed to have clinically improved total gross examination
score (articular cartilage erosion + synovial membrane hemorrhage
score) in their OA joints compared with placebo-treated
control horses. There was also significant decrease in intimal
hyperplasia in the synovial membrane, as well as a decrease
in the histologic cartilage disease score. There was a trend for
a decrease in lameness. Significant decrease in the cartilage
disease points this product toward being a DMOAD.
Kawcak CE, Frisbie DD, McIlwraith, et al. Evaluation of avocado and
soybean unsaponifiable extracts for treatment of horses with experimentally
induced osteoarthritis. Am J Vet Res 2007;68:598-604.[/I]